Pharma Major Lupin’s U.S. subsidiary- Lupin Pharmaceuticals, Inc. (LPI) has received final approval for its Ranolazine Extended release tablets, 500 mg and 1,000 mg from the United States Food and Drugs Administration (FDA). Ranolazine Extended release tablets are indicated for treatment of Chronic angina.
Lupin’s Ranolazine Extended release tablets are the AB rated generic equivalent of Gilead Sciences Ranexa Extended release tablets 500 mg and 1,000 mg strengths. Ranexa tablets 500 mg and 1,000 mg had U.S sales of approximately $443.4 million, for the twelve months ending March, 2013 (IMS Health data).
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: